Radiopharm - Model DUNP19 - Radioactive Drugs
DUNP19 is the invention of Professor Ulmert at UCLA.
-
Most popular related searches
Products Details
DUNP19 is the invention of Professor Ulmert at UCLA.
- DUNP19 'dual action LRRC15 targeting antibody' is a first-in-class small antibody, that has a unique ability to target both tumour and the surrounding tumour micro-environment ('TME') cells, such as stromal and immune cells which comprise more than 50% of tumour masses. Currently available antibodies for cancer treatment generally fail to target TME cells.
- Applicable to a broad range of currently untreatable cancers.
- initial indication will be osteosarcoma, a type of bone cancer that primarily targets children, adolescents and young adults. Osteosarcoma expresses high levels of LRRC15, making it an ideal target for this antibody.
- In September 2022 the FDA granted Orphan Drug Designation and Pediatric Rare Disease designation to DUNP19 in osteosarcoma.
PRECLINICAL DATAHumanized Monoclonal Antibody DUNP19
Customer reviews
No reviews were found for Radiopharm - Model DUNP19 - Radioactive Drugs. Be the first to review!